Short answer · Medically reviewed summary · Last updated: 2026-05-08
Maroteaux-Lamy syndrome, also known as Mucopolysaccharidosis type VI (MPS VI), was first described in 1963 by French physicians Pierre Maroteaux and Maurice Lamy. The discovery marked a turning point in pediatric medicine by identifying the specific biochemical defect that leads to the accumulation of dermatan sulfate in the body's tissues. Who discovered Maroteaux-Lamy syndrome? In 1963, Pierre Maroteaux and Maurice Lamy published their landmark paper detailing the clinical features of patients who presented with severe skeletal deformities, short stature, and corneal clouding, but notably, normal intelligence.
What is the history of Maroteaux-Lamy Syndrome?
History of Maroteaux-Lamy Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Maroteaux-Lamy syndrome, also known as Mucopolysaccharidosis type VI (MPS VI), was first described in 1963 by French physicians Pierre Maroteaux and Maurice Lamy. The discovery marked a turning point in pediatric medicine by identifying the specific biochemical defect that leads to the accumulation of dermatan sulfate in the body's tissues.
Who discovered Maroteaux-Lamy syndrome?
In 1963, Pierre Maroteaux and Maurice Lamy published their landmark paper detailing the clinical features of patients who presented with severe skeletal deformities, short stature, and corneal clouding, but notably, normal intelligence. This distinction helped Maroteaux-Lamy syndrome stand out from other mucopolysaccharidoses (MPS), which were often associated with cognitive decline.
How has our understanding of Maroteaux-Lamy syndrome evolved?
Initially, Maroteaux-Lamy syndrome was characterized purely by its physical clinical presentation. By the 1970s, researchers identified that the condition is caused by a deficiency of the enzyme arylsulfatase B (ARSB). This transition from clinical observation to biochemical understanding allowed for more accurate diagnosis and eventually paved the way for targeted therapies.
What are the major milestones in treatment development?
The management of Maroteaux-Lamy syndrome has shifted from purely supportive care—such as orthopedic surgery and physical therapy—to disease-modifying treatments. Key milestones include:
- 1963: Initial clinical characterization by Maroteaux and Lamy.
- 1970s: Identification of the ARSB enzyme deficiency.
- 2005: FDA approval of Galsulfase (Naglazyme), the first enzyme replacement therapy (ERT) for Maroteaux-Lamy syndrome.
How did genetics change the outlook for the condition?
Modern genetics has confirmed that Maroteaux-Lamy syndrome is an autosomal recessive disorder caused by mutations in the ARSB gene. Genetic counseling now allows families to understand the 25% recurrence risk for siblings, moving the field beyond historical misconceptions that the condition was merely a "failure to thrive" or a random developmental error.
Next steps
- Consult a metabolic specialist or geneticist to confirm your Maroteaux-Lamy syndrome diagnosis.
- Connect with the 3 members living with Maroteaux-Lamy syndrome on DiseaseMaps.org to share experiences.
- Reach out to the National MPS Society for educational resources and support networks.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Maroteaux-Lamy syndrome.
- Orphanet: Mucopolysaccharidosis type VI.
- OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis, type VI; MPS6.
- National MPS Society: Resources for MPS VI.
